Division of Pfizer Inc.
Latest From Hospira Inc.
A look at the evolution of litigation, from Amgen's 'bold' at-risk launch of Herceptin and Avastin biosimilars to the jump in settlements, new battles over manufacturing information and an expected petition to the Supreme Court.
Hybrid 505(b)(2) rivals to Lilly’s Alimta from Dr Reddy’s and Pfizer do not literally infringe a key method-of-treatment patent protecting the pemetrexed brand until May 2022. But their alternative salts infringe under the doctrine of equivalents, the US Court of Appeals has confirmed.
After years of Mylan’s “one quality standard,” the merger with Pfizer Upjohn brings another. Which will prevail? Which should prevail?
Four biosimilar candidates are under US FDA review, including what could be Pfizer’s eighth biologic approved under FDA’s 351(k) biologics license application pathway.
- Diagnostic Imaging Equipment & Supplies
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Drug Delivery
- Generic Drugs
- Therapeutic Areas
- Hospital Products Division (Abbott)
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
F. Michael Ball, CEO
Thomas E Werner, SVP, Fin. & CFO
Sumant Ramachandra, PhD, SVP, CSO
Marc Yoskowitz, SVP, Strategy & Corp. Dev.
- Contact Info
Phone: (224) 212-2000
275 N. Field Dr.
Lake Forest, IL 60045
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.